Results 171 to 180 of about 14,520 (202)

Fulvestrant

DMW - Deutsche Medizinische Wochenschrift, 2006
S, Roth, S, Schaad, V, Hardel, U, Jaehde
openaire   +2 more sources

Fulvestrant

Reactions Weekly, 2023
openaire   +1 more source

Fulvestrant (AstraZeneca).

Current opinion in investigational drugs (London, England : 2000), 2002
Fulvestrant (Faslodex) is an estrogen receptor (ER) downregulator under development by AstraZeneca for the potential treatment of breast cancer [172191], [237518], [314472], [349551]. In March 2001, an NDA was filed in the US for the second-line treatment of advanced breast cancer in postmenopausal women who have progressed on prior hormonal therapy ...
openaire   +1 more source

Fulvestrant

Reactions Weekly, 2016
openaire   +2 more sources

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

European Journal of Cancer, 2022
J Albanell, Luis De La Cruz-Merino, J De La Haba-Rodríguez   +2 more
exaly  

Fulvestrant for advanced breast cancer: A meta-analysis

Cancer Treatment Reviews, 2013
Adrian G Sacher, Alberto Ocaña, FRANCISCO Vera-Badillo   +2 more
exaly  

Abemaciclib/fulvestrant

Reactions Weekly, 2023
openaire   +2 more sources

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

Cancer, 2003
John F R Robertson, C Kent Osborne, Anthony Howell   +2 more
exaly  

Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials

Cancer Treatment Reviews, 2016
Jeffrey Graham, Marshall Pitz, Eitan Amir   +2 more
exaly  

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma

Cancer, 2005
Anthony Howell, John Pippen, Richard M Elledge   +2 more
exaly